alterations,drugs,approvedIndications,level,fdaLevel,levelAssociatedCancerType,levelExcludedCancerTypes,pmids,abstracts,description
['Fusions'],"[{'ncitCode': 'C74061', 'drugName': 'Crizotinib'}]",[],LEVEL_4,LEVEL_Fda3,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}",[],"['29284707', '29102694', '29527595']","[{'link': 'http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.e13539', 'abstract': 'Wang et al. Abstract#e13539, ASCO 2018.'}]","Crizotinib, an inhibitor of ALK, ROS1 and MET tyrosine kinases, is FDA-approved for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive. In a prospective clinical trial of crizotinib in patients with MET fusion-positive lung adenocarcinomas, two of three patients experienced partial responses to treatment with crizotinib (PMID: 29284707). Four other case studies of single patients with MET fusion-positive or kinase-domain-duplication-positive lung cancer documented clinical benefit of crizotinib for these patients, with two of the four patients having a partial response upon crizotinib treatment (PMID: 29527595, 29102694, 29284707)(Abstract: Wang et al. Abstract#e13539, ASCO 2018. http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.e13539). In vitro studies of MET fusions expressed in cell lines have shown that these alterations are sensitive to crizotinib as measured by decreased pathway activation and cell viability upon drug treatment (PMID: 29284707)."
['Fusions'],"[{'ncitCode': 'C74061', 'drugName': 'Crizotinib'}]",[],LEVEL_4,LEVEL_Fda3,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}",[],"['29284707', '29102694', '29527595']","[{'link': 'http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.e13539', 'abstract': 'Wang et al. Abstract#e13539, ASCO 2018.'}]","Crizotinib, an inhibitor of ALK, ROS1 and MET tyrosine kinases, is FDA-approved for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive. In a prospective clinical trial of crizotinib in patients with MET fusion-positive lung adenocarcinomas, two of three patients experienced partial responses to treatment with crizotinib (PMID: 29284707). Four other case studies of single patients with MET fusion-positive or kinase-domain-duplication-positive lung cancer documented clinical benefit of crizotinib for these patients, with two of the four patients having a partial response upon crizotinib treatment (PMID: 29527595, 29102694, 29284707)(Abstract: Wang et al. Abstract#e13539, ASCO 2018. http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.e13539). In vitro studies of MET fusions expressed in cell lines have shown that these alterations are sensitive to crizotinib as measured by decreased pathway activation and cell viability upon drug treatment (PMID: 29284707)."
['Fusions'],"[{'ncitCode': 'C74061', 'drugName': 'Crizotinib'}]",[],LEVEL_4,LEVEL_Fda3,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}",[],"['29284707', '29102694', '29527595']","[{'link': 'http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.e13539', 'abstract': 'Wang et al. Abstract#e13539, ASCO 2018.'}]","Crizotinib, an inhibitor of ALK, ROS1 and MET tyrosine kinases, is FDA-approved for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive. In a prospective clinical trial of crizotinib in patients with MET fusion-positive lung adenocarcinomas, two of three patients experienced partial responses to treatment with crizotinib (PMID: 29284707). Four other case studies of single patients with MET fusion-positive or kinase-domain-duplication-positive lung cancer documented clinical benefit of crizotinib for these patients, with two of the four patients having a partial response upon crizotinib treatment (PMID: 29527595, 29102694, 29284707)(Abstract: Wang et al. Abstract#e13539, ASCO 2018. http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.e13539). In vitro studies of MET fusions expressed in cell lines have shown that these alterations are sensitive to crizotinib as measured by decreased pathway activation and cell viability upon drug treatment (PMID: 29284707)."
['Fusions'],"[{'ncitCode': 'C74061', 'drugName': 'Crizotinib'}]",[],LEVEL_4,LEVEL_Fda3,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}",[],"['29284707', '29102694', '29527595']","[{'link': 'http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.e13539', 'abstract': 'Wang et al. Abstract#e13539, ASCO 2018.'}]","Crizotinib, an inhibitor of ALK, ROS1 and MET tyrosine kinases, is FDA-approved for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive. In a prospective clinical trial of crizotinib in patients with MET fusion-positive lung adenocarcinomas, two of three patients experienced partial responses to treatment with crizotinib (PMID: 29284707). Four other case studies of single patients with MET fusion-positive or kinase-domain-duplication-positive lung cancer documented clinical benefit of crizotinib for these patients, with two of the four patients having a partial response upon crizotinib treatment (PMID: 29527595, 29102694, 29284707)(Abstract: Wang et al. Abstract#e13539, ASCO 2018. http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.e13539). In vitro studies of MET fusions expressed in cell lines have shown that these alterations are sensitive to crizotinib as measured by decreased pathway activation and cell viability upon drug treatment (PMID: 29284707)."
['Fusions'],"[{'ncitCode': 'C74061', 'drugName': 'Crizotinib'}]",[],LEVEL_4,LEVEL_Fda3,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}",[],"['29284707', '29102694', '29527595']","[{'link': 'http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.e13539', 'abstract': 'Wang et al. Abstract#e13539, ASCO 2018.'}]","Crizotinib, an inhibitor of ALK, ROS1 and MET tyrosine kinases, is FDA-approved for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive. In a prospective clinical trial of crizotinib in patients with MET fusion-positive lung adenocarcinomas, two of three patients experienced partial responses to treatment with crizotinib (PMID: 29284707). Four other case studies of single patients with MET fusion-positive or kinase-domain-duplication-positive lung cancer documented clinical benefit of crizotinib for these patients, with two of the four patients having a partial response upon crizotinib treatment (PMID: 29527595, 29102694, 29284707)(Abstract: Wang et al. Abstract#e13539, ASCO 2018. http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.e13539). In vitro studies of MET fusions expressed in cell lines have shown that these alterations are sensitive to crizotinib as measured by decreased pathway activation and cell viability upon drug treatment (PMID: 29284707)."
['Fusions'],"[{'ncitCode': 'C74061', 'drugName': 'Crizotinib'}]",[],LEVEL_4,LEVEL_Fda3,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}",[],"['29284707', '29102694', '29527595']","[{'link': 'http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.e13539', 'abstract': 'Wang et al. Abstract#e13539, ASCO 2018.'}]","Crizotinib, an inhibitor of ALK, ROS1 and MET tyrosine kinases, is FDA-approved for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive. In a prospective clinical trial of crizotinib in patients with MET fusion-positive lung adenocarcinomas, two of three patients experienced partial responses to treatment with crizotinib (PMID: 29284707). Four other case studies of single patients with MET fusion-positive or kinase-domain-duplication-positive lung cancer documented clinical benefit of crizotinib for these patients, with two of the four patients having a partial response upon crizotinib treatment (PMID: 29527595, 29102694, 29284707)(Abstract: Wang et al. Abstract#e13539, ASCO 2018. http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.e13539). In vitro studies of MET fusions expressed in cell lines have shown that these alterations are sensitive to crizotinib as measured by decreased pathway activation and cell viability upon drug treatment (PMID: 29284707)."
['Fusions'],"[{'ncitCode': 'C74061', 'drugName': 'Crizotinib'}]",[],LEVEL_4,LEVEL_Fda3,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}",[],"['29284707', '29102694', '29527595']","[{'link': 'http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.e13539', 'abstract': 'Wang et al. Abstract#e13539, ASCO 2018.'}]","Crizotinib, an inhibitor of ALK, ROS1 and MET tyrosine kinases, is FDA-approved for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive. In a prospective clinical trial of crizotinib in patients with MET fusion-positive lung adenocarcinomas, two of three patients experienced partial responses to treatment with crizotinib (PMID: 29284707). Four other case studies of single patients with MET fusion-positive or kinase-domain-duplication-positive lung cancer documented clinical benefit of crizotinib for these patients, with two of the four patients having a partial response upon crizotinib treatment (PMID: 29527595, 29102694, 29284707)(Abstract: Wang et al. Abstract#e13539, ASCO 2018. http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.e13539). In vitro studies of MET fusions expressed in cell lines have shown that these alterations are sensitive to crizotinib as measured by decreased pathway activation and cell viability upon drug treatment (PMID: 29284707)."
